Predicting response to neoadjuvant therapy (NAT) in patients (pts) with early-stage breast cancer (BC) using circulating tumor DNA (ctDNA) t Published Date June 4, 2024 Expand Fullscreen Exit Fullscreen Download PDF Expand Fullscreen
